1. Academic Validation
  2. MicroRNA-128 knockout inhibits the development of Alzheimer's disease by targeting PPARγ in mouse models

MicroRNA-128 knockout inhibits the development of Alzheimer's disease by targeting PPARγ in mouse models

  • Eur J Pharmacol. 2019 Jan 15;843:134-144. doi: 10.1016/j.ejphar.2018.11.004.
Yanqiu Liu 1 Yuzhen Zhang 1 Ping Liu 2 Hongying Bai 3 Xiaodong Li 3 Jianhao Xiao 3 Qian Yuan 3 Shuang Geng 1 Honglei Yin 1 Hui Zhang 1 Zhen Wang 1 Jinfeng Li 4 Shanshan Wang 1 Yunliang Wang 5
Affiliations

Affiliations

  • 1 Department of Neurology, PLA 960 Hospital, Zibo, Shandong 255300, China.
  • 2 Department of Neurology, Central Hospital of Zibo, Zibo, Shandong 255000, China.
  • 3 Department of Neurology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450014, China.
  • 4 Department of Oncology, Chinese PLA General Hospital, Beijing 100037, China.
  • 5 Department of Neurology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450014, China. Electronic address: [email protected].
Abstract

Alzheimer's disease (AD) is a great threat for the health and life of elderly people. MicroRNA-128 (miR-128) has been reported to be abnormally expressed in the brain of AD patients and associated with the pathogenesis of AD. Our study aimed to have a deep insight into the roles and molecular basis of miR-128 in the development and progression of AD. The cognitive ability and exploratory behaviors were assessed by morris water maze and open-field tests, respectively. The concentrations of Amyloid-β (Aβ) 40, Aβ 42, tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 and activity of β-secretase and α-secretase were determined by corresponding ELISA commercial kits. RT-qPCR assay was performed to detect miR-128 level and the mRNA expression of Peroxisome Proliferator-activated Receptor gamma (PPARγ), ionized calcium-binding adaptor molecule 1 (Iba1) and glial fibrillary acidic protein (GFAP). Western blot assay was conducted to determine protein expression of PPARγ, amyloid precursor protein (APP), β-APP cleaving Enzyme (BACE1), sAPPα and sAPPβ. The effect of miR-128 and PPARγ on amyloid plaque formation was assessed by immunohistochemistry assay. PPARγ mean optical density was determined by immunofluorescence assay. The interaction between miR-128 and PPARγ were validated by bioinformatics analysis and luciferase reporter assay. We found AD mice showed AD-like performance and an increased cerebral cortex Aβ production. MiR-128 expression was upregulated and PPARγ expression was downregulated in cerebral cortex of AD mice. Moreover, PPARγ was a target of miR-128. Additionally, miR-128 knockout or PPARγ upregulation inhibited AD-like performances, amyloid plaque formation, Aβ generation, APP amyloidogenic processing and inflammatory responses in AD mice, while these effects of miR-128 knockout were abrogated by PPARγ Inhibitor. The results indicated MiR-128 knockout weakened AD-like performances, and reduced Aβ production and inflammatory responses by targeting PPARγ in AD mice.

Keywords

3×Tg-AD triple transgenic mouse model; Alzheimer's disease; PPARγ; miR-128.

Figures
Products